GSK seeks US FDA blessing for GLP-1 albiglutide in Type II diabetes
This article was originally published in Scrip
GlaxoSmithKline is seeking the US FDA's approval to market the London-based drug maker's experimental glucagon-like peptide-1 (GLP-1) receptor agonist albiglutide as a once-weekly treatment for adults with Type II diabetes – revealing on 14 January that it had submitted a biologics license application (BLA) to the agency.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.